Company Encyclopedia
View More
name
Assembly Biosciences
ASMB.US
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study. The company also develops ABI-7423, an oral broad-spectrum non-nucleoside polymerase inhibitor that targets transplant-related herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc.
1.946 T
ASMB.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking119/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-36.94%E
    • Profit Margin-103.65%E
    • Gross Margin-53.74%E
  • Growth ScoreA
    • Revenue YoY31.30%A
    • Net Profit YoY5.53%C
    • Total Assets YoY139.37%A
    • Net Assets YoY602.59%A
  • Cash ScoreC
    • Cash Flow Margin-96.48%D
    • OCF YoY31.30%A
  • Operating ScoreD
    • Turnover0.22D
  • Debt ScoreB
    • Gearing Ratio23.88%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Assembly Biosciences (NASDAQ:ASMB) Stock Price Crosses Above Two Hundred Day Moving Average - Here's Why

    Assembly Biosciences (NASDAQ:ASMB) stock price crossed above its 200-day moving average, trading as high as $39.65. Analysts have given mixed ratings, with a consensus target price of $41.00. The company reported a quarterly EPS of ($0.72), missing estimates. Institutional investors have made significant changes to their positions in ASMB. The company develops therapeutic candidates for viral diseases, including herpes and hepatitis delta virus.

    Market Beat·
    US
    ASMB
    +0.77%
    Market Beat·
    US
    ASMB
    +0.77%

    Mizuho Securities Reaffirms Their Buy Rating on Assembly Biosciences (ASMB)

    Mizuho Securities analyst Salim Syed reaffirmed a Buy rating on Assembly Biosciences (ASMB) with a price target of $40. H.C. Wainwright also issued a Buy rating, while another firm reiterated a Hold rating. Syed, who covers the Healthcare sector, has an average return of -4.1% and a 41.09% success rate on stock recommendations.

    Tip Ranks·
    US
    ASMB
    +0.77%
    Tip Ranks·
    US
    ASMB
    +0.77%

    FY2027 Earnings Estimate for ASMB Issued By HC Wainwright

    HC Wainwright analysts lowered FY2027 EPS estimates for Assembly Biosciences from $1.67 to $1.44, maintaining a "Buy" rating with a $50 price target. The consensus for current full-year earnings is ($6.87) per share. Other analysts have varied ratings, with a consensus of "Moderate Buy" and an average target price of $41.25. Institutional investors have been active in trading ASMB shares, which opened at $36.71 with a market cap of $281.64 million.

    Market Beat·
    US
    ASMB
    +0.77%
    Market Beat·
    US
    ASMB
    +0.77%

    Assembly Biosciences: Strong Clinical Execution and Strategic Partnerships Drive Buy Rating

    Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Assembly Biosciences with a $50 target, citing strong clinical execution in HSV, HDV, and HBV areas. Key developments include ABI-5366's success in HSV trials and promising results for ABI-6250 in HDV. The strategic partnership with Gilead Sciences enhances Assembly's position. Guggenheim also reiterated a Buy rating with a $39 target. Trucchio is a top analyst with a 34.8% average return.

    Tip Ranks·
    US
    ASMB
    +0.77%
    Tip Ranks·
    US
    ASMB
    +0.77%

    Assembly Biosciences Inc. Reports Q3 2025 Earnings

    Assembly Biosciences Inc. reported its Q3 2025 earnings, highlighting collaboration revenue of $10.8 million, up from $6.8 million year-over-year. Operating expenses increased to $21.7 million, leading to a net loss of $9.2 million. However, the company improved its financial position with cash and marketable securities totaling $232.6 million. Assembly raised $175 million through stock sales and continues its partnership with Gilead Sciences, focusing on advancing its investigational therapies and maintaining optimism about funding operations beyond the next year.

    Tip Ranks·
    US
    ASMB
    +0.77%
    Tip Ranks·
    US
    ASMB
    +0.77%
    © 2025 Longbridge｜Disclaimer